BLRX - BioLineRx Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3550
-0.0050 (-1.39%)
At close: 4:00PM EDT

0.3600 +0.01 (1.41%)
After hours: 5:41PM EDT

Stock chart is not supported by your current browser
Previous Close0.3600
Open0.3550
Bid0.3550 x 2200
Ask0.3800 x 800
Day's Range0.3550 - 0.3700
52 Week Range0.3500 - 0.4500
Volume238,751
Avg. Volume1,831,400
Market Cap52.782M
Beta (3Y Monthly)3.10
PE Ratio (TTM)N/A
EPS (TTM)-0.1990
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
Trade prices are not sourced from all markets
  • BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade
    Zacks5 days ago

    BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade

    BioLineRx (BLRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • PR Newswire8 days ago

    BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019 Management to hold conference call today, May 14, at 10:00 am EDT TEL AVIV, Israel , May 14, 2019 /PRNewswire/ ...

  • PR Newswire15 days ago

    BioLineRx to Report First Quarter 2019 Results on May 14, 2019

    Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced ...

  • PR Newswire15 days ago

    BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors

    TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors. "We are pleased with the FDA's IND approval, which will enable us to expand our ongoing Phase 1/2a study, currently being carried out in the UK and Israel, to the US by the first half of 2020," said Philip Serlin, Chief Executive Officer of BioLineRx.

  • ACCESSWIRE21 days ago

    Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report ...

  • PR Newswire2 months ago

    BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update

    BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months Management to hold conference call today, March 28, at 10:00 am EDT TEL AVIV, Israel , March ...

  • ACCESSWIRE2 months ago

    Four Tech Stocks Sparking Activity on Wednesday

    Companies across the tech industry are pulling out all the stops to allocate resources for the development of innovative technology. Nowadays, consumers are outwardly vocal about the products they are interested in, and some companies in the tech sector have managed to meet the growing demands of consumers in the tech market. All in all, the future is largely unpredictable, but if the tech industry continues to develop exciting, advanced products and services to improve our quality of life, this could catalyze serious investor attention.

  • PR Newswire2 months ago

    BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients

    TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the  GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 and G-CSF to G-CSF alone, in mobilization of HSCs for autologous transplantation in multiple myeloma patients. "Autologous HSC transplantation in multiple myeloma has been shown to improve overall survival compared to conventional chemotherapy.

  • PR Newswire2 months ago

    BioLineRx to Report Annual 2018 Results on March 28, 2019

    Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , March 21, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...

  • PR Newswire2 months ago

    BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference

    TEL AVIV, Israel , March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, ...

  • PR Newswire3 months ago

    BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

    TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

  • PR Newswire3 months ago

    BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

    TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. Copies of the final prospectus supplement may also be obtained, when available, from Oppenheimer & Co. Inc., 85 Broad St., 26th Floor, New York, New York 10004, Attention: Syndicate Prospectus Department, or by telephone: (212) 667-8055 or by email: EquityProspectus@opco.com.

  • ACCESSWIRE3 months ago

    Biotech on the Brink of Breaking Out

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now. One of the best examples of the ...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...

  • PR Newswire3 months ago

    BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants

    TEL AVIV, Israel, Feb. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of its ordinary shares with each ADS to be sold together in a fixed combination with a warrant to purchase ADSs. BioLineRx anticipates using the net proceeds from the proposed offering for general corporate purposes, which may include, but are not limited to, working capital and funding clinical trials.

  • ACCESSWIRE3 months ago

    Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)

    Over time, in an effort to further these advancements in the healthcare industry, legislators have sought to pass positive legislation in favor of legalizing marijuana, resulting in the passing of the US Farm Bill as well as other laws around the world. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Can-Fite BioPharma Ltd (CANF), BioLineRx Ltd (BLRX), and Aurora Cannabis Inc., (ACB) represent four cannabis companies determined to develop nuanced approaches for integrating cannabis as a means for improving the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • PR Newswire4 months ago

    BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

    BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead oncology candidate, BL-8040, for the treatment of pancreatic cancer. BL-8040 is currently being investigated in clinical studies for the treatment of pancreatic cancer under two separate immuno-oncology collaborations – one with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), and a second collaboration with Genentech, a member of the Roche Group.

  • PR Newswire5 months ago

    BioLineRx to Present at the 2019 Biotech Showcase

    TEL AVIV, Israel , January 2, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that management ...

  • PR Newswire5 months ago

    BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration

    TEL AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in patients with metastatic pancreatic cancer (PDAC) under its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada). As previously announced, the triple combination arm will investigate the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy.

  • PR Newswire5 months ago

    BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference Center near Grand Central Terminal in New York, N.Y. BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4 in late clinical development for the treatment of solid tumors, acute myeloid leukemia (AML) and stem-cell mobilization for bone-marrow transplantation.

  • ACCESSWIRE6 months ago

    New Healthcare Trends Have Investors Looking at 4 Stocks

    Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

  • PR Newswire6 months ago

    BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134

    TEL AVIV, Israel, Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted the Biological Product Designation for AGI-134, the Company's novel immunotherapy compound. This designation provides the Company with eligibility to obtain 12 years of market exclusivity upon approval of the product for commercial use by the FDA.